CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
Liposomal Cytarabine-Daunorubicin CPX-351 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01804101
NCT01804101N/ACompleted
CompareCT.gov

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Fred Hutchinson Cancer Center·interventional·Posted Mar 5, 2013·Updated May 25, 2018

In Brief

A clinical study evaluating Laboratory Biomarker Analysis and Liposomal Cytarabine-Daunorubicin CPX-351 for Acute Biphenotypic Leukemia and 3 related conditions. Completed, enrolled 48 participants across 2 sites.

Detailed Summary

This randomized clinical trial studies liposomal cytarabine-daunorubicin CPX-351 in treating patients with untreated myelodysplastic syndrome or acute myeloid leukemia. Drugs used in chemotherapy, such as liposomal cytarabine-daunorubicin CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 5, 2013
Enrollment StartMay 7, 2013
Primary CompletionJan 10, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 13.3 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Liposomal Cytarabine-Daunorubicin CPX-351drug

Given IV